Meeting
2019 Gastrointestinal Cancers Symposium
Comparison of HER2 expression by immunohistochemistry and HER2 copy number by digital PCR in tumor tissue during treatment with trastuzumab in the prospective cohort of metastatic HER2-positive gastric cancer patients.
Authors
Naoki Takahashi
Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan
Naoki Takahashi , Satoru Iwasa , Tomohiro Matsushima , Shoichi Miyazawa , Yosuke Kumekawa , Satoshi Shimizu , Takako Yoshii , Masako Asayama , Hiroki Hara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Translational Research
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 58)
DOI
10.1200/JCO.2019.37.4_suppl.58
Abstract #
58
Poster Bd #
G8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Computational pathology–based HER2 quantification to identify novel biomarkers in gastric cancer (GC).
First Author: Ansh Kapil
Poster
2015 Gastrointestinal Cancers Symposium
Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.
First Author: Ozge Gumusay
Poster
2017 Gastrointestinal Cancers Symposium
Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of GASTric cancer HER2 reassessment study 3 (GASTHER3).
First Author: Seyoung Seo
Poster
2015 Gastrointestinal Cancers Symposium
Lapatinib combined with ECF/x as first-line metastatic gastric cancer (GC) according to HER2 and EGFR status: A randomized placebo controlled phase II (EORTC 40071).
First Author: Markus Hermann Moehler